Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 119fludarabine phosphate 97Cytarabine 86fludarabine 74Methotrexate 70Rituximab 68Busulfan 56Whole-Body Irradiation 48Filgrastim 48Tacrolimus 43Mycophenolic Acid 43Antilymphocyte Serum 40Etoposide 37Peripheral Blood Stem Cell Transplantation 36Granulocyte Colony-Stimulating Factor 35Melphalan 34Vincristine 33Alemtuzumab 33Cyclosporine 32Clofarabine 30Azacitidine 30Dexamethasone 29Imatinib Mesylate 26thymoglobulin 25Doxorubicin 23sargramostim 22Lenalidomide 22Methylprednisolone 20Stem Cell Transplantation 19Daunorubicin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia × lorvotuzumab mertansine × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡